Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Invested Capital (2016 - 2025)

United Therapeutics (UTHR) has disclosed Invested Capital for 17 consecutive years, with $7.1 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 5.22% to $7.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 billion through Dec 2025, up 5.22% year-over-year, with the annual reading at $7.1 billion for FY2025, 5.22% up from the prior year.
  • Invested Capital hit $7.1 billion in Q4 2025 for United Therapeutics, up from $6.6 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $7.2 billion in Q2 2025 to a low of $3.4 billion in Q1 2021.
  • Historically, Invested Capital has averaged $5.4 billion across 5 years, with a median of $5.6 billion in 2023.
  • Biggest five-year swings in Invested Capital: surged 33.11% in 2023 and later rose 1.37% in 2025.
  • Year by year, Invested Capital stood at $4.0 billion in 2021, then rose by 21.16% to $4.8 billion in 2022, then skyrocketed by 33.11% to $6.4 billion in 2023, then rose by 5.63% to $6.7 billion in 2024, then grew by 5.22% to $7.1 billion in 2025.
  • Business Quant data shows Invested Capital for UTHR at $7.1 billion in Q4 2025, $6.6 billion in Q3 2025, and $7.2 billion in Q2 2025.